One-third of cancer patients undergoing chemotherapy treatment often display symptoms of depression leading to poor adherence and decreased quality of life. Thus, this study aimed to investigate the possible protective effect of nebivolol against cisplatin-associated depressive symptoms in adult male rats. Nebivolol is a highly cardioselective b-adrenergic receptor blocker that possesses endothelium-dependent vasodilator properties and antioxidant capacities. Animals were allocated into four groups. Group one was given aqueous solution of carboxymethyl cellulose and served as control, group two was given nebivolol (10 mg/kg p.o., daily), group three was given cisplatin (2 mg/kg i.p. once per week) for 10 consecutive weeks and group four was treated with cisplatin concomitantly with nebivolol as per above schedule. Cisplatintreated rats showed an increase in both depressive-like behaviors in open-field and forced swimming tests. In addition, histopathological examination revealed cortical encephalomalacia along with hippocampal neuronal degeneration and kidney dysfunction. In parallel, cisplatin administration prominently reduced GABA and elevated glutamate levels in the cortical and hippocampal tissues. Furthermore, it resulted in a significant decline in cortical and hippocampal brain-derived neurotrophic factor and nitric oxide contents concomitantly with a marked decrease in endothelial-and an increase in inducible-nitric oxide synthase genes expression. On the other hand, treatment with nebivolol effectively mitigated the aforementioned cisplatin-associated behavioral, biochemical, and histopathological alterations without changing its antitumor activity as evidenced by sulforhodamine B cell survival assay. Taken together, our results suggest that nebivolol may offer a promising approach for alleviating depressive symptoms associated with the use of cisplatin.
Cancer diagnosis and treatment are considered some of the most life-changing events as they can impact the patient's mental and psychological abilities. It was estimated that cancer patients undergoing chemotherapy treatment display symptoms of depression and anxiety with an incidence of 12-24% (Linden et al. 2012) . Surgical operations to remove the tumor as well as radio-and chemotherapies have often been associated with an induction of depressive symptoms, memory deficits, and cognitive decline in relevant patients (Ganguli 2009 ). These mood-related deficits occur mostly in patients with pancreatic, gastric, head and neck, and lung cancers (Silver et al. 2013) . As a rebuttal to cancer associated depression, it might be convincingly stated that poor regimen adherence will follow depressive symptoms causing the patient to suffer from long-term hospitalization, suicidal ideation, and decreased quality of life (Yohannes and Alexopoulos 2014) . Therefore, more attention should now be paid to exploring new agents or treatment strategies with a view to increasing patient compliance.
Cisplatin is a highly effective antineoplastic DNAalkylating agent used to treat many types of tumors (Sanchez-Gonzalez et al. 2011) . However, its dose-dependent nephrotoxicity is considered one of its main limitations (Leu and Baribeault 2010; dos Santos et al. 2012) . There is an unambiguous relationship between the changes in the central nervous system and uremic toxins caused by the alterations in the hormonal activities within brain in patients with chronic kidney disease (Hedayati et al. 2012; Zalai et al. 2012) . Furthermore, direct neurotoxicity in the form of acute alterations in consciousness, seizures, cerebral infarctions, paralysis, neuropathy, and ototoxicity is a common and often dose-limiting complication of cisplatin-treatment (Beinert et al. 2000; Cavaliere and Schiff 2006) . The drug also causes apoptosis (Kong et al. 2013) and DNA damage (Li and Schluesener 2006) and induces oxidative stress and inflammation (Chirino and Pedraza-Chaverri 2009; Kang et al. 2009 ). Furthermore, Waseem and Parvez (2013) argue that cisplatin causes neurotoxicity by damaging the mitochondria. Therefore, much research has been focused on the identification and understanding of the molecular and biochemical mechanisms of neuroprotectants against such toxicities (Bianchi et al. 2006) . Although there are few studies reporting some cognitive complaints in cancer patients on cisplatin (Pedersen et al. 2009) , studies on the effect of cisplatin on the affective domain of organism's interaction with stimuli are still lacking. In this context, it seemed of interest to further extend these previous observations by investigating the possible effects of cisplatin on some selected behavioral parameters.
A recent research paper pointed toward reduced cancerrelated psychological distress in cancer patients using betablockers (Lindgren et al. 2013) . These findings lend support to the claim that beta-blockers use may benefit cancer patients' psychological adjustment following diagnosis, and open a promising door for future investigations on the pharmacological benefits of beta-blockers for cancer-related distress. Nebivolol is a relatively new highly cardioselective b-adrenergic receptor antagonist that possesses endotheliumdependent vasodilator properties and antioxidant capacities (Cockcroft 2007) . Moreover, it is a highly lipophilic drug that increases the likelihood of treating the psychological abnormalities associated with cancer treatment (Karter 2007) .
Since there are no reports on the ability of nebivolol to treat these affective abnormalities, it is very important to delineate its ability to ablate the psychological dysfunction associated with cisplatin treatment. Therefore, this work shed light on the effects of nebivolol on the behavioral parameters in the open field and the forced swimming tests. In addition, biochemical parameters were measured in rats' cortex and hippocampus as it is known to be one of the most important brain structures implicated in depression. Moreover, the histopathological changes in these structures along with the kidney were examined. Finally, the antitumor activity of cisplatin was tested in the presence and absence of nebivolol. Hence, this work aims to determine the extent to which nebivolol can affect cisplatin-induced depression-like behaviors as well as its effect on cisplatin antitumor activity.
Materials and methods

Animals
Adult male Wistar rats (170-200 g, 6-8 weeks old) were provided by the animal facility of Faculty of Pharmacy, Cairo University, Egypt. Animals were housed in groups of three or four per cage (50 9 30 9 30 cm) under standard laboratory temperature conditions (25 AE 2°C), relative humidity (about 60%), with a 12/12 h light/dark cycle (lights on/off at 7:00 am/19:00 pm), and free access to food and water. Experiments were conducted during the light phase of the cycle. All experiments were performed according to the protocol approved by our Institutional Ethics Committee for Animal Care and Use (Permit Number: 1350) in strict accordance with the international policies (Guide for Care and Use of Laboratory Animals published by the US National Institute of Health; NIH Publication No. 85-23, revised 1996) . All efforts were made to minimize animal suffering, to reduce the number of animals used, and to utilize alternatives to in vivo techniques, if possible.
Chemicals
Nebivolol was a gift from Marcyrl Pharmaceutical Industries (Cairo, Egypt). Cisplatin was purchased from Sigma-Aldrich (St. Louis, MD, USA). All other chemicals were of the highest purity and analytical grade.
Experimental design
Three independent experiments (N) were performed in this study. The first one was a preliminary experiment aimed to explore the hemodynamic action of nebivolol. Twenty-four rats were randomly allocated by a technical assistant not involved in the analysis into one of four treatments (n = 6), as follows:
Vehicle (Control): Rats were given 0.5% aqueous solution of carboxymethyl cellulose on a daily basis for 10 consecutive weeks. Nebivolol (NBV): Animals were treated with nebivolol (10 mg/ kg p.o. via an oral syringe; suspended in 0.5% aqueous solution of carboxymethyl cellulose) on a daily basis for 10 consecutive weeks (Heeba and El-Hanafy 2012) . Cisplatin (CIS): Animals were treated with cisplatin (2 mg/kg i.p.; dissolved in saline) once on a weekly basis for 10 consecutive weeks (Ramya et al. 2011) . Cisplatin + nebivolol (NBV + CIS): Animals were treated with cisplatin concomitantly with nebivolol as per above schedule.
Systolic blood pressure was measured at weeks 5 and 10 by the non-invasive tail cuff using PowerLab data acquisition system (AD Instruments, Bella Vista, New South Wales, Australia) as previously described by Mansour et al. (2011) .
The second experiment had been performed for behavioral, biochemical, western, and histopathological analyses. Fifty-six rats were randomly allocated into one of four treatments (16 rats each), based on a power analysis (power = 0.8, a = 0.05) using effect sizes previously determined by Golchin et al. (2015) and Shabani et al. (2012) , where animals were treated with vehicle (Control), NBV, CIS, or cisplatin + nebivolol (NBV + CIS); as per the schedule described above in the first experiment. At the end of nebivolol administration, rats performed the behavioral tests. The tests were arranged in sequence from the least stressful test to the most stressful one as in the following sequence: open field test then forced swimming test, which were conducted during the light phase (Liu et al. 2016) . On the next day, animals were anesthetized with thiopental (5 mg/kg, i.p.) and blood samples were collected from the retro-orbital sinus using non-heparinized capillary tubes for serum separation to estimate creatinine and blood urea nitrogen. Thereafter, rats were split into three sets (6, 6, and 4 rats), killed by decapitation and brains were immediately excised, rinsed with ice-cold saline, and subsequently cortex and hippocampus were promptly dissected out. At the end of the experiment, dead animals and animals' debris were frozen until incineration. Cortical and hippocampal tissues of one set (n = 6) were used for estimation of the biochemical parameters glutamate, GABA, brain-derived neurotrophic factor (BDNF) and nitric oxide (NO), and those of the second set (n = 6) were used for western blot analysis to estimate endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) proteins expression. In the last set (n = 4), brains and kidneys were collected for histopathological examination.
The third experiment aimed to assess the antitumor effect of nebivolol as well as its effect on the cytotoxic profile of the standard cisplatin using the sulforhodamine B assay method (n = 3). During sample analysis of all the previous experiments, the investigators were blinded to sample identity, where sample coding and decoding were carried out by an independent investigator.
Behavior assessments
Open field test The experiment was performed in a square wooden box (80 9 80 9 40 cm) whose bottom was divided into 16 equal squares (20 9 20 cm). Each rat was individually placed in the center of the open field and allowed to freely explore the area for 3 min. After each test the floor and walls were cleaned to eliminate possible bias because of odors left by previous rats. A video camera was fixed on the top of the box to record behavior of rats for later off-line analysis. Ambulation (number of squares crossed) and rearing (number of times the animal stood on hind limbs) as well as immobility time (time elapsed with lack of movement during testing) were recorded (van den Buuse and de Jong 1989) .
Forced swimming test
Depressive-like behavior was assessed as previously described (Cryan et al. 2001) . Rats were individually forced to swim for 5 min in a plexi-glass cylindrical tank (height 80 cm; diameter 30 cm) filled with water (25 AE 1°C) to a depth of 40 cm. The tank was cleaned and filled with fresh water between experiments. Immobility time (when no additional movements other than those necessary to keep the rat head off the water) was recorded (Cryan et al. 2002) . At the end of experiment, each rat was dried and placed back into their home cage.
Biochemical measurements
Measurement of serum creatinine and blood urea nitrogen Blood urea nitrogen and Serum creatinine concentrations were estimated by colorimetric assay through a method described by Hallett and Cook (1971) with a Bio-Diagnostic kit (Biodiagnostic, Cairo, Egypt).
Glutamate, GABA, and BDNF estimation Cortical and hippocampal contents of glutamate, GABA, and BDNF were quantified by ELISA technique using the purchased kits from Abnova Corporation (Jhongli, Taiwan), Wuhan EIAab Science Co. Ltd (Wuhan, China) and KAMIYA Biomedical Co. (Seattle, WA, USA), respectively, according to the manufacturer's protocol.
Nitric oxide estimation
Cortical and hippocampal NO level was quantified as total nitrate/ nitrite based on the method of Miranda et al. (2001) . Nitrate was reduced to nitrite using vanadium trichloride, and, consequently, Griess reagent was rapidly added and the produced pink azo-dye was measured colorimetrically at 540 nm.
Western blot analysis
Cortical and hippocampal eNOS and iNOS protein expressions were analyzed using western blot methodology. In brief, cortex and hippocampus were homogenized in lysis buffer, centrifuged at 14 000 g at 4°C for 30 min and then quantified for protein levels using a commercial assay kit (Thermo Fisher Scientific Inc., Rockford, IL, USA). An aliquot of 20 lg protein from each sample was separated on 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Amersham Bioscience, Piscataway, NJ, USA) using a semidry transfer apparatus (Bio-Rad, Hercules, CA, USA). Membranes were blocked with 5% nonfat milk in Trisbuffered saline with 0.05% Tween-20 (TBST) at 4°C overnight. The membranes were then washed with TBST and incubated with a 1 : 2000 dilution of antibodies to eNOS and iNOS (Stressgen Biotechnologies, Victoria, BC, Canada) for 1 h at room temperature of 25 AE 2°C with constant shaking. The filters were washed and subsequently probed with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin (Amersham, Life Science Inc., Arlington Heights, IL, USA). Chemiluminescence detection was performed with the Amersham detection kit according to the manufacturer's protocols and exposed to X-ray film. The amount of NOS protein was quantified by densitometric analysis of the autoradiograms using a scanning laser densitometer (Biomed Instrument Inc., Brooklyn, NY, USA). Results were expressed as arbitrary units after normalization for b-actin protein expression .
Histopathological examination
Autopsy samples were taken from the kidney and brain of four rats per group and fixed in 10% formol saline for 24 h. Washing was done in tap water then serial dilutions of alcohol (methyl, ethyl, and absolute ethyl alcohol) were used for dehydration. Specimens were cleared in xylene and embedded in paraffin at 56°C in hot air oven for 24 h. Paraffin bees wax tissue blocks were prepared for sectioning at 4 microns thickness by slidge microtome. The obtained tissue sections were collected on glass slides, deparaffinized, stained by hematoxylin and eosin stain for routine examination through the light electric microscope (Banchroft et al. 1996) .
Measurement of potential cytotoxicity by sulforhodamine B (SRB) assay Potential cytotoxicity of cisplatin, nebivolol, and their combination were tested using the method of Skehan et al. (1990) . The human breast cancer (MCF-7), prostate (PC-3), colon (HCT), and liver (HepG2) cancer cell lines were obtained from the Holding Company for Production of Vaccines, Sera and Drugs (Cairo, Egypt). The procedure was done in a sterile area using a laminar air flow cabinet. Culture was maintained in Roswell Park Memorial Institute (RPMI) 1640 medium with 1% antibiotic-antimycotic mixture (10 000 U/ mL potassium penicillin, 10 000 lg/mL streptomycin sulfate, and 25 lg/mL amphotericin B), 1% L-glutamine, and supplemented with 10% heat inactivated fetal bovine serum. Culturing and subculturing were carried out according to Thabrew et al. (1997) . MCF-7, PC-3, HCT or HepG2 were plated in 96-multiwell plate (104 cells/well) for 24 h before treatment with the compounds to allow attachment of cell to the wall of the plate. Different concentrations of the compounds under test (0.5, 1, 2, 4, 8, 16, 32, 62, 125, 250, 500 , and 1000 lg/mL) were added to the cell monolayer triplicate wells which were prepared for each individual dose. Monolayer cells were incubated with the compounds for 48 h at 37°C and in atmosphere of 5% CO 2 . After 48 h, cells were fixed, washed and stained with Sulforhodamine B stain. Excess stain was washed with acetic acid and attached stain was recovered with Tris EDTA buffer. Color intensity was measured in an ELISA reader. The relation between surviving fraction and drug concentration was plotted to get the survival curve of each tumor cell line after the specified compound.
Statistical analysis
Data were expressed as means AE SD. Comparisons between means were carried out using one-way ANOVA followed by Tukey's post hoc test except for the ambulation and rearing frequencies of the open field test which were done by KruskalWallis ANOVA followed by Dunn's post hoc test and blood pressure measurements which were done by Two-way ANOVA followed by Tukeys post hoc test; p < 0.05. Statistical analysis was performed using GraphPad Prism software version 5 (San Diego, CA, USA); a probability level of less than 0.05 was accepted as statistically significant.
Results
Effect of nebivolol on systolic blood pressure This study revealed that administration of cisplatin and nebivolol did not change the systolic blood pressure throughout the experimentation period (Fig. 1) .
Effect of nebivolol on cisplatin-induced changes in rats' behavior in the open field and forced swimming tests Cisplatin-treated rats showed an increase in depression-like behavior including decreased ambulation and rearing frequencies to attain 33 and 29% of the control rats, respectively, in the open field along with increased immobility time in both the open field and forced swimming tests by 2.4 and 3.1 folds, respectively, of the control group. Nebivolol treatment significantly reduced the aforementioned behavioral changes in cisplatin-treated rats. The drug prominently increased ambulation and rearing by 121% and 139%, respectively, whereas it decreased immobility time in both behavioral tests by 30% and 35% as compared to cisplatin group (Table 1) .
Effect of nebivolol on cisplatin-induced changes in cortical and hippocampal GABA and glutamate levels Cisplatin administration significantly reduced GABA level by 32% and 36% (Fig. 2 a and b ), but it elevated glutamate level by 31% and 53% (Fig. 2 c and d) in the cortical and hippocampal tissues, respectively, as compared to the corresponding values of the control group, which were reversed by nebivolol treatment. Fig. 1 Effect of nebivolol on systolic blood pressure. Each value represents the mean AE SD (N = 1, n = 6). Statistical analysis was performed by two-way ANOVA followed by Tukeys post hoc test; p < 0.05. NBV, nebivolol; CIS, cisplatin. Effect of nebivolol on cisplatin-induced changes in cortical and hippocampal BDNF level BDNF level in cortex and hippocampus of cisplatin-treated rats was significantly declined to 73% and 65% of the corresponding control group, which were almost reverted back to their normal values by nebivolol treatment (Fig. 2 e and f). Effect of nebivolol on cisplatin-induced changes in cortical and hippocampal NO level as well as eNOS and iNOS protein expressions Cisplatin administration caused a substantial decline in NO level (60% and 70%) concomitant with a marked decrease in eNOS expression (29% and 34%) and increase in iNOS expression (405% and 308%) in the cortical and hippocampal tissues, respectively, compared to control group. However, nebivolol treatment effectively normalized NO level in cortex and hippocampus (Fig. 2 g and h) . In addition, nebivolol prominently increased eNOS protein expression by 128% and 113% and decreased iNOS expression by 58% and 50% in the cortical and hippocampal tissues, respectively, compared with the cisplatin group (Fig. 2 i & j) .
Effect of nebivolol on cisplatin-induced changes in urea and creatinine blood levels Cisplatin administration caused a significant elevation in both urea and creatinine levels, attaining 235% and 184% of the corresponding control group, respectively. Administration of nebivolol concurrently with cisplatin showed a reduction in urea level by 43.63% and creatinine level by 26.89% compared to cisplatin group (Fig. 3) .
Effect of nebivolol on cisplatin-induced histopathological changes in rats' brain Cisplatin group showed focal hemorrhage, encephalomalacia, neuronal degeneration along with apoptotic degeneration in the cerebral cortex (cerebrum) and hippocampus. On the other hand, nebivolol treatment more or less normalized the aforementioned alterations (Table 2 , Fig. 4 ).
Effect of nebivolol on cisplatin-induced histopathological changes in rats' kidney Cisplatin-induced tubular cystic dilatation as well as congestion in the cortical blood vessels in association with inflammatory cells infiltration with extravasted red blood cells were noticed between the degenerated and necrosed tubules. Administration of nebivolol reduced inflammatory cells infiltrates and showed homogenous eosinophilic cast in some tubular lumen (Table 2, Fig. 5 ).
Cell survival assay
The SRB assay demonstrated that nebivolol inhibits cell proliferation in a dose-dependent manner. Fig. 6 shows the dose-response cell survival curves for nebivolol in MCF-7, PC-3, HCT, and HepG2 cells compared to a common chemotherapeutic agent (cisplatin) as well as to combination of both agents. As shown in Fig. 6 , the IC50 values of nebivolol in the four cell cultures were 25.9 AE 1.37 lg/mL, 141.7 AE 18.93 lg/mL, 82.33 AE 2.52 lg/mL, and 56.67 AE 7.64 lg/mL, respectively, which were significantly higher than the values of cisplatin as well as nebivolol combined with cisplatin groups. There was no significant change in the IC50 between groups of cisplatin alone and cisplatin combined with nebivolol in MCF-7, PC-3, and HepG2 cells, whereas a significant decrease in the IC50 of cisplatin after combining it with nebivolol was observed in HCT cells. These findings indicate that nebivolol has an inhibitory effect on cancer cell proliferation but less than cisplatin and it did not affect the antitumor activity of cisplatin. Statistical analysis was performed by oneway ANOVA followed by Tukeys post hoc test; p < 0.05. NBV, nebivolol; CIS, cisplatin. 
Discussion
Although cisplatin is an effective widely used antineoplastic drug, its use is limited because of its serious adverse effects including neurotoxicity and nephrotoxicity. In the present work, cisplatin administration was associated with depressive-like behavior in rats as evidenced in the adopted behavioral tests. Reduced motor activity was observed in the open field test and manifested as a decrease in both ambulation and rearing frequencies as well as an increase in immobility time. In addition, depressive-like behavior was also noted as prolonged immobility time in the forced swimming test. These data are in harmony with previous studies that showed that cisplatin administration impaired explorative behaviors, memory retention, locomotor activity in rats (Shabani et al. 2012; Golchin et al. 2015) .
The relationship between the use of beta-blockers and depression is still unclear. In this study, nebivolol decreased significantly the depressive-like behavior in both open field and forced swimming tests. In line with our results it was recently shown that atenolol exhibited antidepressant effects by significantly reducing the immobility and inducing the swimming behavior in the modified forced swim test (Shahzad et al. 2014) . Moreover, Lindgren et al. (2013) illustrated that cancer patients treated with beta-blocker endorsed less cancer-related intrusive thoughts as emotional memories, nightmares, flashbacks, and intrusive images than non-users. The neuroprotective effect of nebivolol was also confirmed by reverting the histopathological changes associated with cisplatin as focal hemorrhage, encephalomalacia and neuronal degeneration in both cerebral cortex and hippocampus. Such neuroprotective effect may not be correlated with nebivolol's hemodynamic action, as it did not alter the blood pressure in normal rats, in agreement with previous studies (Peters et al. 2003; Ceron et al. 2013) .
The relationship between the emotional and cognitive changes associated with depression and the excitatory transmission was established in several previous studies. Fig. 4 Cisplatin-induced histopathological changes in rats' brain. Representative photomicrographs of the rats' brain of normal control group (Control) showed normal histological structure of the meninges, cerebral cortex 'c', and hippocampus 'hp'; nebivolol group (NBV) showed no histopathological alteration in cortex and hippocampus; cisplatin group (CIS) showed focal hemorrhage 'h' with encephalomalacia 'nc' in cerebrum and the pyramidal cells showed degeneration and apoptosis 'd' in some of them and neuronal degeneration and encephalomalacia in the matrix of hippocampus; cisplatin + nebivolol group (CIS + NBV) showed no histopathological alteration in the cortex and hippocampus. NBV, nebivolol; CIS, cisplatin.
For instance, patients suffering from mood disorders had glutamatergic abnormalities in cerebrospinal fluid, brain tissue and plasma. In addition, the glutamate content was elevated in depressed patients as compared to the normal healthy subjects (Mitani et al. 2006; Kucukibrahimoglu et al. 2009 ). Confirming the previous findings, antidepressants treatment was associated with a decrease in the plasma glutamate level (Maes et al. 1998; Kucukibrahimoglu et al. 2009 ). Furthermore, a similar relationship was found between abnormalities in GABA content and mood and cognitive dysfunction (Tunnicliff and Malatynska 2003; Sanacora and Saricicek 2007) . In the present investigation, cisplatin administration was associated with a reduction in GABA and an elevation in glutamate contents in rats' hippocampi and cortex. This effect was reversed by preadministration of nebivolol. In the same line, Okuda et al. (1999) demonstrated that intravenous propranolol was accompanied by a significant decline in the release of the excitatory amino acid glutamate.
In fact, both humans and animal models of depression show less expression of BDNF than their comparable control subjects (Duman and Monteggia 2006) . Also, the level of BDNF and the expression of its receptor showed a marked decline in hippocampi of patients suffering from major depressive disorder (Autry and Monteggia 2012) . It was also reported that the reduction in BDNF mRNA level in the hippocampus and prefrontal cortex may contribute to the depressive-like behavior in the lipopolysaccharide treated rats (Jia et al. 2015) . Herein, nebivolol treatment amended the decline in BDNF level after cisplatin treatment. In the same line, chronic administration of the nicotinic cholinoreceptor antagonist mecamylamine amended chronic restraint stress-induced depressive-like behavior as evidenced by decreasing immobility in forced swimming test and central zone duration in open field test via increasing the level of BDNF (Aboul-Fotouh 2015) . Similarly, propranolol reverted the changes in markers of synaptic pathology in Alzheimer's transgenic mice following the induction of BDNF (Dobarro Fig. 5 Cisplatin-induced histopathological changes in rats' kidney. Representative photomicrographs of the rats' kidney of normal control group (Control) showed normal histological structure of the glomeruli 'g' and tubules 't' at the cortex and the tubules at the corticomedullary portion; nebivolol group (NBV) showed no histopathological alteration; cisplatin group (CIS) showed tubular cystic dilatation 'cs' as well as congestion in the cortical blood vessels 'v' in association with inflammatory cells infiltration with extravasted red blood cells 'h' were noticed between the degenerated 'd' and necrosed 'n' tubules. Also the corticomedullary portion showed homogenous eosinophilic casts 'c' in the lumen of some tubules with cystic dilatation and degeneration in the lining epithelium of the others; cisplatin + nebivolol group (CIS + NBV) showed inflammatory cells infiltration between the degenerated and cystically dilated tubules at the cortex and the corticomedullary portion showed homogenous eosinophilic cast in some tubular lumen with degeneration in the lining epithelium of others. NBV, nebivolol; CIS, cisplatin. et al. 2013) . Hence, the psychological abnormalities shown with cisplatin in this model may lie in the significant decline in BDNF after cisplatin treatment.
Although, nitric oxide (NO) is widely reported to be involved in the regulation of the nervous system, debate continues about its role whether it causes or treats depressive behaviors. The modulation of nitric oxide in the brain by using inhibitors for NOS enzyme reduced the depressive actions associated with chronic stress (Joca and Guimaraes 2006; Sevgi et al. 2006; Dhir and Kulkarni 2007) . Moreover, a previous study showed that pre-treating mice with an iNOS inhibitor significantly diminished the depressive behaviors induced by unpredictable chronic mild stress (Peng et al. 2012 ). In addition, many reports have confirmed the role of NO in the behavioral despair associated with many disorders. For instance, mice with Crohn's disease demonstrated a significantly higher immobility time in the forced swimming test associated with a significant elevation in iNOS expression and nitrite content. However, acute NOS inhibition decreased the immobility time in colitic mice (Heydarpour et al. 2016) . Collectively, the previous work suggests that elevated serum NO level is associated with depressive-like behavior. On the other hand, Kordjazy et al. (2015) showed that the elevated level of NO is responsible for the antidepressant effect of rubidium chloride in mice as coadministration of l-NAME with the effective dose of rubidium chloride and reversed its anti-immobility effect. Our results clarified this clouded area and added new evidence strengthening the results reached by Kordjazy et al. (2015) as the depressive-like behaviors induced by cisplatin in this model was associated with a decline in NO content in rats' hippocampi and cortex together with a reduction in eNOS activity in both tissues. Also, treatment with nebivolol together with cisplatin increased the NO content as well as eNOS and iNOS activities. This elevation in NO content after the third generation b-adrenolytics, nebivolol, may lead to beneficial NO-dependent vasodilator properties that augment in their therapeutic efficacy. For instance, nebivolol administration inhibited ischemia/reperfusion-induced depletion of reduced glutathione level, increased eNOS gene expression, with simultaneous decrease in iNOS gene expression in a dose dependent manner. In addition, nebivolol significantly reduced infarct volume and ameliorated histopathological changes induced by ischemia/reperfusion. This neuroprotection observed with nebivolol may be explained by regulating eNOS and iNOS gene expressions as well as by inhibiting the oxidative stress-induced injury (Heeba and El-Hanafy 2012) . In addition, after acute urea loading, NO production was decreased in mice hippocampi and those mice exhibited depression-like behavior (Li et al. 2012) .
Depressive symptoms are common in patients with chronic kidney disease (Loosman et al. 2015) . Ali et al. (2014) demonstrated that cisplatin induced all the classical physiological, histological, and biochemical alterations associated with acute renal failure and these changes were associated with decreased motor and exploration activities, and increased immobility time in depression models, presenting a possible depression-like state Ali et al. (2014) . Cisplatininduced nephrotoxicity, evidenced herein by the elevated urea and creatinine levels as well as the renal histopathological changes, was associated with the observed depressive-like behavior in rats, an effect that was abated by nebivolol. Similarly, carvedilol showed effective chemoprotectant properties as it resulted in a significant decline in the levels of blood urea nitrogen and serum creatinine, markers related to nitrosative stress, oxidative stress, inflammation, and apoptosis as well as histopathological abnormalities in kidney tissues induced by potassium dichromate (Sahu et al. 2014) .
Finally, this study is considered the first inquiry to show that nebivolol, the new beta blocker, is active against MCF-7, PC-3, HCT, and HepG2 cell lines. The SRB assay in our study indicated that nebivolol reduced survival in MCF-7, PC-3, HCT, and HepG2 cell lines but with an IC50 significantly higher than that of cisplatin. In addition, no change was shown in the IC50 of cisplatin when combined with nebivolol in MCF-7, PC-3, and HepG2 cell lines, whereas only HCT cell line showed a reduction in IC50 of cisplatin when combined with nebivolol. These results clearly indicate that nebivolol either did not affect the antitumor effect of cisplatin. Previous reports are in line with our conclusions as there were many findings to support the antitumor activity of beta blockers. For instance, carvedilol prevented skin carcinogenesis (Chang et al. 2015) and propranolol inhibited cell proliferation and induced apoptosis in human melanoma cell lines (Wrobel and Le Gal 2015) .
In conclusion, our findings clearly indicate that cisplatin use is associated with depression. This psychological dysfunction occurs either directly through changing the neurotransmitters levels as well as histopathological abnormalities or indirectly as a consequence of nephrotoxicity. It is now possible to state that nebivolol can diminish the depressive-like behaviors associated with cisplatin without affecting its antitumor activity. Therefore, our results add new evidence for the ameliorative effects of the new beta blocker nebivolol and highlight the need for further experimental and clinical studies that will define the clinical scope of therapy with nebivolol as a sole agent or an adjunctive therapy for patients suffering from psychoactive abnormalities as a consequence of cancer itself or its treatment.
